Psioxus Therapeutics | Date: 2016-08-08
The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
Psioxus Therapeutics | Date: 2015-02-27
The present disclosure relates to a process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Ad11, in particular Ad11p also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps: a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step. The disclosure also extends to formulations and viruses obtained from the process.
Psioxus Therapeutics | Date: 2015-04-13
The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer. 5ITR-B_(1)-B_(A)-B_(2)-B_(X)-B_(B)-B_(T)-B_(3)-3ITR (I)
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2011-ITN | Award Amount: 3.86M | Year: 2012
ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to train young scientists in adenovirus (AdV) research. Our full partners and industrial partners represent internationally leading academic centres of excellence in key facets of research into the basic biology of AdV and their application as vectors for clinical protocols in cancer, cardiovascular disease and vaccination that is unique as a training opportunity. Our academic and private sector full partners represent a key areas critical to improved understanding of adenovirus biology and development of key underpinning technology for translational AdV research at the highest level and will create a training opportunity of the highest calibre. The training components are further complemented by our associated partners EASCO that will integrate into ADVance a broad interdisciplinary training and dissemination program. This will ensure the very best training in scientific and key non-scientific skills for each recruited ESRs and ERs. We have also recruited Glen Nemerow as a visiting researcher for his depth of understanding and experience in AdV research over many years. ESR will benefit extensively from the complementarity between the host institutes and strength in depth in training for future careers as well as elevated long term research links for host institutes and companies in the longer term. The network research training is based on a group of well defined and highly innovative research projects applying state-of-the-art methodologies. ADVance will allow lasting collaborations between partners, with and extensive plan of inter-partners secondments of ESR/ERs, which will and create a critical mass of focused adenovirus biologists and translationnal scientists and allow our recruited young researchers to start an excellent career in this field
Psioxus Therapeutics | Date: 2014-12-23
The present disclosure relates to a method of making an adenovirus plasmid comprising a part or all of an adenovirus genome and one or more original restriction sites allowing rapid and flexible manipulation of the adenovirus genome, and methods of preparing adenovirus constructs, for example comprising a transgene. The disclosure also extends to novel intermediates employed in and generated by the method, to plasmids and shuttle vectors of the method and to adenoviruses or adenoviral vectors obtainable from the plasmid and/or method. The disclosure further relates to use of the viruses or vectors, for example obtained from a method disclosed herein, in therapy, such as use in the treatment of cancer.
Psioxus Therapeutics | Date: 2014-08-20
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.73M | Year: 2013
ColoAd1 is a chimeric adenovirus serotype 3/11p, with a number of key characteristics that may make it a suitable oncolytic agent for the potential treatment of metastatic carcinomas. This is a phase I/IIa study designed to determine the safety, toxicity and tolerability of ColoAd1 and the clinical benefit and potential efficacy of ColoAd1 as a single agent and in combination with chemotherapy in women with recurrent platinum resistant ovarian cancer when administered intraperitoneally. Safety evaluations will be will be assessed using NCI CTCAE v4 and efficacy evaluations will be assessed using CT and [18F]-FDG PET/CT scans. A number of pharmacogenomics and biomarker assessments will also be performed.
Psioxus Therapeutics | Date: 2014-10-24
The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5ITR-B1-BAB2-BX-BB-BY-B3-3ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
Psioxus Therapeutics | Date: 2014-02-28
The present disclosure relates to a process for the manufacture of adenoviruses wherein the process comprises culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and at the end of the culturing period isolating from the media the adenovirus by filtering wherein the isolation of virus is not subsequent to a cell lysis step and to viruses obtainable from the process.
Psioxus Therapeutics | Date: 2014-06-12
The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 110^(10 )to 110^(14 )viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 210^(10 )particles per minute to 210^(12 )particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.